LONGEVERON INC-A
LGVNNASDAQTrading Snapshot
- Day Range
- $0.73 – $0.75
- 52-Week Range
- $0.48 – $1.27
- Volume
- $2.15B
- Avg Volume
- $1.93B
- Shares Outstanding
- 31.6M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $398,000
- P/E Ratio
- —
- P/S Ratio
- 19.1x
- EPS (TTM)
- $-1.17
- Dividend Yield
- —
Why Investors Own LGVN
- ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About LONGEVERON INC-A
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.